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Clinical risk factors for underlying gastrointestinal 
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Abstract: Objective: Ten percent of adults presenting with iron deficiency anaemia 
(IDA) have underlying cancer. This study was undertaken to prospectively validate 
the observation in a previous retrospective study that three simple clinical parame-
ters can usefully predict the likelihood of gastrointestinal (GI) malignancy on inves-
tigation of patients with IDA, and to screen for other potential clinical predictors of 
risk. Method: Observational study of a cohort of 643 subjects attending an IDA clinic 
at a District General Hospital between 2012 and 2015, with multivariable analysis 
of the predictive value of a series of clinical variables including sex, age and hae-
moglobin concentration ([Hb]) for underlying GI malignancy. Results: Analysis of the 
validation cohort data confirmed the original observation that sex, age, and Hb were 
associated with the risk of GI malignancy—the parsimonious model including only 
these variables yielded odds ratios of 1.9 (95% confidence interval (CI): 1.1, 3.3) for 
males vs. females; 1.6 (95% CI: 0.9, 2.9) for age >70 vs. ≤70 years; and 2.9 (95% CI: 
1.2, 6.9) for [Hb] <90.6 g/l vs. >112 g/l. Combining data from the observation and val-
idation cohorts (total n = 1,363) identified sub-groups with cancer risks ranging from 
0% to over 20%. No other predictive clinical variables were identified. Conclusions: 
Three simple and objective clinical parameters can be combined to provide a clini-
cally useful cancer risk stratification model for subjects with IDA. This may assist 
with patient counselling and the prioritisation of investigational resources.
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publications resulting from data generated by 
this clinic. It provides prospective validation of the 
previous observation that subjects with IDA can 
be stratified according to cancer risk by the use of 
three simple clinical criteria – age, sex and severity 
of anaemia. The risk in sub-groups ranges from 
less than 2% to over 20%, and so can usefully 
inform clinical decision-making.
Follow-on studies are underway aiming to 
further enhance this risk stratification system.
PUBLIC INTEREST STATEMENT
Iron deficiency anaemia (IDA) is a common 
medical condition. In about 10% of cases it is 
caused by an underlying cancer of the stomach 
or bowel, and it is often the first indication of this 
problem. Current guidelines therefore recommend 
that everyone with IDA should undergo endoscopy 
to examine these areas.
This study reports a detailed analysis of 643 
patients with IDA. It confirms that the risk of 
underlying cancer can be predicted by three simple 
clinical criteria—age, sex and severity of anaemia.
The importance of this is that it identifies a 
sub-group of patients at high risk of cancer, who 
therefore warrant urgent investigation. It also 
identifies a sub-group at low risk of cancer, who 
may not require invasive investigation at all.
Received: 22 June 2016
Accepted: 07 July 2016
First Published: 25 July 2016
© 2016 The Author(s). This open access article is distributed under a Creative Commons Attribution 
(CC-BY) 4.0 license.
Page 1 of 7
Page 2 of 7
Wijayasekara et al., Cogent Medicine (2016), 3: 1213216
http://dx.doi.org/10.1080/2331205X.2016.1213216
Subjects: Gastroenterology; Hematology; Oncology
Keywords: gastrointestinal malignancy; iron deficiency anaemia
1. Introduction
Iron deficiency anaemia (IDA) is a common clinical problem, with an overall incidence in excess of 
one case per 1,000 pa. Published case series have consistently shown that about 30% of males and 
post-menopausal females with IDA have significant underlying gastrointestinal (GI) pathology, with 
malignancy accounting for about a third of these, often in the absence of clear clinical pointers to 
the diagnosis (Camaschella, 2015; Liu & Kaffes, 2012; Pasricha et al., 2010; Rockey, 1999; Surgenor, 
Kirkham, Parry, Williams, & Snook, 2014).
The IDA clinic at Poole Hospital has been operational since 2004, and is the point of referral for the 
many patients with IDA who have minimal or no symptoms to indicate the nature or location of the 
underlying cause of iron deficiency (Surgenor et al., 2014). Basic patient data has been collected 
since inception for the purpose of clinical care, audit and service evaluation. The referral rate to the 
IDA clinic approaches 300 new patients per annum.
It is current standard practice to advise urgent investigation of IDA, on the grounds that there 
might be an underlying cancer (Goddard, James, McIntyre, & Scott, 2011). A simple but reliable pre-
test predictor of risk would therefore help considerably with patient counselling. It could also im-
prove the use of resources, with prioritisation of high-risk subjects for fast-track investigation, and 
perhaps avoidance of invasive investigation altogether in particularly low-risk individuals.
Previous work by our group and others (James, Chen, Goddard, Scott, & Goddard, 2005; Silva et al., 
2014) has demonstrated that three simple and objective clinical variables—age, sex and haemoglo-
bin concentration—appear to be strong and independent predictors of underlying GI malignancy in 
IDA. In the IDIOM study (Silva et al., 2014), the combination of these variables was used to derive a 
score corresponding to the percentage probability of underlying GI malignancy—which ranged from 
less than 2% in low-risk subgroups to more than 20% in high-risk subgroups. These studies do how-
ever have the shortcomings that both were retrospective in design and lacked an a priori hypothe-
sis—simply because there was insufficient evidence to base such a hypothesis on.
The aims of this study were twofold. Firstly to provide prospective validation of the independent 
variables identified in the original IDIOM study as predictors of underlying GI malignancy. Secondly 
to determine whether other clinical variables might be additional predictors of GI malignancy risk in 
IDA.
2. Method
Anonymised clinical data were collected prospectively for all 643 new patients added to the Poole 
Hospital IDA register between 2012 and 2015, for whom information on the final diagnosis was 
available—the validation cohort. This data included age, sex, haemoglobin concentration [Hb], 
mean red cell volume (MCV), mean cell haemoglobin (MCH), erythrocyte sedimentation rate (ESR), 
family history (FH) of GI cancer, recent unexplained weight loss (>3 kg), use of regular aspirin and/or 
anti-inflammatory medications (ASA/NSAIDs) and final diagnosis.
Essentially the methodology and investigation algorithm used was as detailed in our previous 
paper (Silva et al., 2014). IDA was confirmed on the basis of iron studies. All patients were investi-
gated by means of a gastroscopy and colonic examination—colonoscopy in most cases, CT colonog-
raphy in a minority. The follow-up period concluded once these investigations had been undertaken. 
About 10% of subjects were unwilling, unable or not fit enough to complete these investigations, 
and were excluded from the analysis.
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The predictive value of those variables shown to be independent risk factors for GI malignancy in 
the original IDIOM study (Silva et al., 2014) were compared for the original observation cohort of 720 
subjects seen prior to 2012 reported in that study, and for this validation cohort. Subjects from the 
validation cohort with a complete data-set were used to screen for additional clinical variables that 
might be independent predictors of GI malignancy risk in IDA.
Least square regression analysis was used to determine which of the different patient character-
istics and clinical variables predicted the occurrence of GI cancer. As the dependent variable was a 
dichotomous categorical variable, models used logistic regression. All analyses were undertaken 
using STATA (version 13) software, the aim being to identify a parsimonious model that provided the 
most appropriate explanation of variations in the occurrence of GI malignancy. As the study design 
was entirely observational and anonymous, the National Research Ethics Service deemed that for-
mal Research Ethics Committee approval was not required.
3. Results
The validation cohort comprised 643 subjects, of whom 423 (65.8%) were female. The median age 
of this group was 71.3 years (IQR: 60.1–79.0), and the median [Hb] 103 g/l (IQR: 90.5–112.0). A total 
of 61 (9.5%) proved on investigation to have GI cancer.
Multivariate analysis revealed that age, sex and [Hb] were independent predictors of the risk of GI 
malignancy in the validation cohort. The odd ratios tended to be marginally closer to unity than in 
the observation cohort, and the figure for age didn’t quite reach statistical significance (Table 1). A 
sub-group analysis for the 16 combinations of these three variables for the pooled data is shown in 
Table 2, with the relationship summarised in a 3 dimensional bar chart (Figure 1). There was a wide 
spectrum of absolute GI malignancy risk, ranging from 0% in females under 70 with mild anaemia 
to 24% in males over 70 with more severe anaemia.
Of the 643 subjects in the validation cohort, 315 had a complete data-set for all variables—and 
the characteristics of this cohort are shown in Table 3. Multivariate analysis revealed no additional 
independent predictors of GI cancer risk amongst the variables analysed. The absence of an ESR 
Table 1. Odds ratios (95% confidence intervals) for parsimonious multiple logistic regression 
models of the clinical variables associated with GI malignancy for the observation and 
validation cohorts (Poole Hospital 2004–2015)
Note: RC-Reference category.
 *Haemoglobin quartiles (g/L): Observation cohort-Q1: >111.4, Q2: 102.5–111.4, Q3: 91.5–102.4, Q4: <91.5, Validation 
cohort-Q1: >112.0, Q2: 103.1–112.0, Q3: 90.6–103.0, Q4: <90.6, Combined cohort-Q1: >112.0, Q2: 102.1–112.0, Q3: 
90.1–102.0, Q4: <90.0.
Variable Observation cohort 
n = 720
Validation cohort 
n = 643
Combined cohorts 
n = 1,363
Sex
 Female RC RC RC
 Male 4.0 (2.3, 7.0) 1.9 (1.1, 3.3) 2.8 (1.9, 4.0)
Age
 ≤70 RC RC RC
 >70 3.3 (1.7, 6.4) 1.6 (0.9, 2.9) 2.2 (1.4, 3.3)
Haemoglobin quartile*
 Q1 RC RC RC
 Q2 1.6 (0.6, 4.3) 1.2 (0.5, 3.1) 1.4 (0.7, 2.8)
 Q3 2.5 (1.1, 6.1) 2.5 (1.1, 6.1) 2.9 (1.6, 5.4)
 Q4 5.3 (2.4, 11.7) 2.9 (1.2, 6.9) 3.8 (2.1, 7.0)
Pseudo R2 18% 4% 8%
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result was the commonest reason for an incomplete data-set, and there were no major differences 
in the characteristics of those subjects excluded from the analysis due to missing data.
4. Discussion
Malignancy is the most important GI pathology underlying IDA. Several retrospective multivariate 
analyses have attempted to identify clinical risk factors predictive of GI malignancy in subjects with 
IDA, with generally rather discordant conclusions (Capurso et al., 2004; Ho et al., 2005; James et al., 
2005; Silva et al., 2014). However, some of these studies were relatively small and therefore likely to 
be underpowered, and none had a validation cohort. The combined data-set of well over 1,000 sub-
jects with IDA presented in this paper is far larger than any published study on this topic.
The IDIOM (Iron Deficiency as an Indicator Of Malignancy) study demonstrated that age, sex and 
[Hb] are moderately strong independent predictors of underlying GI malignancy in patients with IDA 
(Silva et al., 2014)—in agreement with the largest previous analysis from Nottingham (James et al., 
Table 2. The percentage prevalence (with 95% CIs) of GI malignancy in 16 subgroups by sex, 
age and haemoglobin quartile of 1,363 subjects with IDA (Poole Hospital 2004–2015). Absolute 
numbers for each sub-group are shown immediately below
Hb quartile: g/L Female ≤70 years Female >70 years Male ≤70 years Male >70 years
Q1: >112.0 0 (0, 6.4) 4.1 (0.7, 15.1) 2.5 (0.4, 9.7) 12.2 (6.8, 20.8)
0/71 2/49 2/79 12/98
Q2: 102.1–112.0 0 (0, 4.0) 5.7 (2.7, 11.2) 7.3 (1.9, 21.0) 15.5 (8.3, 26.4)
0/115 8/141 3/41 11/71
Q3: 90.1–102.0 5.6 (2.3, 12.3) 10.1 (5.9, 16.7) 22.2 (9.4, 42.7) 18.7 (10.9, 29.7)
6/107 14/138 6/27 14/75
Q4: <90.1 7.1 (3.2, 14.6) 13.8 (8.7, 20.9) 18.1 (8.7, 33.2) 23.9 (14.9, 35.8)
7/98 19/138 8/44 17/71
Figure 1. The percentage 
prevalence of GI malignancy 
in 16 subgroups by sex, age 
and haemoglobin quartile 
of 1,363 subjects with IDA 
(Poole General 2004–2015). 
Haemoglobin quartile ranges 
are as in Table 2.
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2005). Whilst the odds ratios tend to be smaller and the relationship with age is only borderline sig-
nificant, the current study now provides prospective validation of this observation. It also demon-
strates that other clinical variables do not appear to add usefully to cancer risk prediction.
Because these three clinical predictors are independent, they collectively provide a powerful pre-
dictor tool for cancer risk, as shown by the sub-group breakdown of the combined data-set pre-
sented in Table 2 and Figure 1, providing IDIOM scores equivalent to the percentage prevalence of 
GI malignancy. The risk broadly rises with worsening anaemia in each age/sex sub-group. At one 
extreme, none of 186 females under the age of 70 with mild anaemia proved to have underlying 
cancer, even though the majority of this group were post-menopausal. At the other end of the spec-
trum, GI malignancy was identified in over 20% of 217 males with more severe anaemia.
Why is risk stratification in IDA important? Many patients with unexplained IDA have minimal or 
no symptoms, and in view of the well-recognised cancer risk, fast-track referral for bidirectional en-
doscopy (BDE) is considered best practice regardless of age, sex or degree of anaemia (Goddard et 
al., 2011). However, BDE carries a small but significant risk of major complications—especially in 
older patients and those with major co-morbidities. It is also a labour-intensive process that places 
a significant burden on Endoscopy Departments—each BDE can take up to an hour to complete 
thoroughly, and we estimate that 5–10% of all GI endoscopy procedures are for the investigation of 
IDA. Yet the overall yield of this approach is relatively poor, with only 1 in 10 patients proving to have 
malignant pathology.
Validation of a simple risk stratification system is important because it is a tool that would help 
clinicians to counsel patients regarding the risk/benefit ratio of invasive investigation, and to target 
those investigations more appropriately (Kaminski et al., 2014; Snook, 2014; Wong et al., 2014). In 
particular, a case could be made for avoiding invasive investigation in low risk sub-groups as long as 
they exhibit a sustained haematological response to iron replacement therapy. It is worth 
Table 3. Univariate odds ratios (95% CIs) and significance levels for the associations between 
other clinical characteristics and GI malignancy in 315 subjects (Poole Hospital 2012–2015)
Variable Percent (n) with GI malignancy Odds ratio (95% CI) p-value
MCV (fl) Q1: >86.4 9% (7) RC
Q2: 80.3–86.4 4% (3) 0.4 (0.1, 1.6) 0.20
Q3: 74.2–80.3 13% (10) 1.5 (0.6, 4.3) 0.41
Q4: ≤74.1 14% (11) 1.6 (0.6, 4.5) 0.33
MCH (pg) Q1: >27.5 8% (6) RC
Q2: 25.4–27.5 9% (7) 1.2 (0.4, 3.6) 0.79
Q3: 22.8–25.3 8% (6) 1.0 (0.3, 3.3) 0.98
Q4: ≤22.7 15% (12) 2.1 (0.7, 5.9) 0.16
ESR (mm/hr) Q1: >54 10% (8) 1.4 (0.5, 4.3) 0.54
Q2: 38–54 10% (8) 1.4 (0.5, 4.3) 0.54
Q3: 22–37 11% (9) 1.6 (0.5, 4.7) 0.40
Q4: ≤21 8% (6) RC
Weight loss (>7lbs) No 9% (22) RC
Yes 11% (9) 1.2 (0.5, 2.7) 0.66
Regular ASA/NSAID No 12% (22) RC
Yes 7% (9) 0.6 (0.3, 1.3) 0.16
FH GI cancer No 10% (27) RC
Yes 8% (4) 0.8 (0.3, 2.4) 0.67
Page 6 of 7
Wijayasekara et al., Cogent Medicine (2016), 3: 1213216
http://dx.doi.org/10.1080/2331205X.2016.1213216
highlighting that several of these low-risk IDIOM sub-groups have a cancer risk that is less than the 
arbitrary threshold of 3% currently advocated for the justification of fast-track referrals from pri-
mary care in the UK. At the other end of the spectrum, subjects in high-risk IDIOM sub-groups clearly 
warrant swift investigation.
How good a risk stratifcation system is the IDIOM score? The perfect stratification system would 
allocate all subjects to a low-risk or high-risk sub-group with 0 or 100% risk respectively, but this is 
rarely achievable in clinical practice. A more pragmatic assessment might be to consider the propor-
tion of patients in stratification sub-groups with a risk that is more than double or less than half of 
the overall mean population risk. The figures of 7 and 23% respectively for our combined data-set 
compare favourably with those from other recently published cancer risk stratification systems 
(Kaminski et al., 2014; Wong et al., 2014).
Can the IDIOM risk stratification system be improved further? This remains to be established, but 
we believe that it might be. Faecal occult blood (FOB) testing is a simple and non-invasive investiga-
tion that has already been shown to be of some value in identifying patients with IDA due to under-
lying GI malignancy (Chowdhury, Longcroft-Wheaton, Davis, Massey, & Goggin, 2014; Cilona, Zullo, 
Hassan, Ridola, & Annese, 2011; Majid, Salih, Wasaya, & Jafri, 2008; Nakama, Zhang, Fattah, & Zhang, 
2011). We are currently exploring the possibility of combining FOB testing with the IDIOM score to 
assess whether this further enhances risk stratification.
In conclusion, the original IDIOM study derived a model to predict the risk of underlying GI malig-
nancy in patients with IDA based on their age, sex and [Hb]. This has been prospectively validated in 
the present study, which has not revealed any additional significant clinical predictors of risk. The find-
ings provide a simple yet valuable method of clinical risk stratification for individual patients with IDA.
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